Should I Buy ATYR? ATYR 2026 Analysis

Should You Buy aTyr Pharma Inc (ATYR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.900

1 Day change

10.85%

52 Week Range

7.290

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now (at $0.96 pre-market). Price is pressing into near-term resistance while momentum is overextended.
If you already own it: this is a reasonable area to trim/sell into strength near R1 $0.975 (then R2 $1.063) given the short-term downside bias.
Near-term edge is weak: no Intellectia buy signals today + pattern stats imply a higher probability of drift lower over the next day/week/month.
What could change the view: a cleaner pullback toward $0.834 (pivot) or $0.693 (S1), or a clear breakout/hold above $0.975–$1.063 on strong volume.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram +0.0318 and expanding (bullish momentum), but RSI(6) ~ 82 signals overbought conditions and increased pullback risk.
Moving averages: converging MAs suggest a potential inflection, but with RSI stretched, the more probable immediate path is chop/pullback rather than a clean continuation.
Key levels:
- Support: $0.834 (pivot), then $0.693 (S1), then $0.606 (S2)
- Resistance: $0.975 (R1), then $1.063 (R2)
Quant/pattern read: similar-pattern stats show ~~70% odds of modest declines (**~~ -1.24% next day**, -1.84% next week, -1.97% next month)—not favorable for an impatient “buy now” entry near resistance.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning (Open Interest): Put/Call OI 0.18 (call-heavy), which can be interpreted as bullish longer-horizon positioning.
Today’s trading (Volume): Put/Call volume 3.43 with puts 1170 vs calls 341 → bearish/defensive near-term sentiment.
Activity: total options volume 1511, about 107% of 30-day average (elevated attention).
Volatility: 30D IV ~205.95% (very high); IV percentile ~57.6 (still elevated vs typical). This often coincides with sharp moves, but today’s volume skew suggests traders are leaning protective/negative into the very short term.

Technical Summary

Sell

Buy

Positive Catalysts

- Event catalyst: FDA granted a Type C meeting in mid-April 2026 to discuss EFZO-FIT results—this can support speculative rebounds into the meeting.
- Narrative support: despite missing the primary endpoint, news notes some clinical benefits, which can keep the story “alive” and sustain trading interest.
- Insider activity: Insiders are Buying, with buying amount up ~5978.67% over the last month (a meaningful positive signal on confidence/valuation at these levels).

Neutral/Negative Catalysts

- Overhang: the Phase 3 EFZO-FIT trial failed its primary endpoint, which remains the dominant fundamental risk.
- Short-term technical risk: overbought RSI + trading near R1 resistance increases odds of a near-term fade.
- Options tape: heavy put volume dominance today suggests traders are positioning for downside or hedging aggressively.
- Timing: next major catalyst (FDA meeting) is not immediate (mid-April), leaving room for the stock to drift lower beforehand.

Financial Performance

Latest quarter: 2025/Q3
Revenue: $190K, essentially flat YoY (0.00%) — still very low commercial scale.
Profitability: Net income - $25.744M, improved +49.16% YoY (loss narrowing), but still meaningfully negative.
EPS: -0.26, improved +13.04% YoY.
Takeaway: financial trend shows cost/loss improvement, but the company remains highly dependent on clinical/regulatory outcomes rather than operating revenue momentum.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided in the dataset.
Wall Street-style pro view (based on what we do have): insider buying + an FDA meeting scheduled can support speculative upside bursts.
Wall Street-style con view: Phase 3 miss and minimal revenue base keep risk elevated; without a clear new success signal, upside tends to be news-driven and fragile.

4 Analyst Rating

Wall Street analysts forecast ATYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATYR is 7.33 USD with a low forecast of 1 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

3 Hold

0 Sell

Hold

Current: 0.811

Low

Averages

7.33

High

Current: 0.811

Low

Averages

7.33

High

Leerink

Faisal Khurshid

Outperform

maintain

$NULL

AI Analysis

2025-09-15

Reason

Leerink

Faisal Khurshid

Price Target

$NULL

AI Analysis

2025-09-15

maintain

Outperform

Reason

Leerink analyst Faisal Khurshid keeps an Outperform rating on aTyr Pharma after the company said the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint of steroid reduction. While aTyr plans to engage with the FDA on a potential path forward, Leerink's expectations are low given the primary endpoint miss and unclear relevance of KSQ-Lung score improvements alone, the analyst tells investors in a research note. Going into the readout, the firm expected a primary endpoint miss would see 80%-90% share downside. aTyr Pharma shares are down 82%, or $4.97, to $1.07 in early trading.

Cantor Fitzgerald

Overweight -> Neutral

downgrade

2025-09-15

Reason

Cantor Fitzgerald

Price Target

2025-09-15

downgrade

Overweight -> Neutral

Reason

Cantor Fitzgerald downgraded aTyr Pharma to Neutral from Overweight after the company announced that the Phase 3 pulmonary sarcoidosis trial for efzofitimod missed the primary endpoint of change in mean steroid dose from baseline at week 48. aTyr plans to engage with the FDA to determine the path forward, but the firm doesn't have much confidence in the path forward for efzo in pulmonary sarcoidosis, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATYR

Unlock Now

ATYR Should I Buy

ATYR Should I Buy

Should You Buy aTyr Pharma Inc (ATYR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch